Advanced Cell Technology to Present at Stem Cell Meeting on the Mesa’s 2nd Annual Investor and Partnering Forum

  Advanced Cell Technology to Present at Stem Cell Meeting on the Mesa’s 2nd
  Annual Investor and Partnering Forum

Business Wire

MARLBOROUGH, Mass. -- October 26, 2012

Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of
regenerative medicine, announced today that chairman and CEO Gary Rabin will
present at the 2012 Stem Cell Meeting on the Mesa’s Investor and Partnering
Forum, Oct. 29 and 30 in La Jolla, California.

In his presentation, Mr. Rabin will provide an overview of ACT’s ocular
programs. The presentation will be webcast by theAlliance for Regenerative
Medicinein the weeks following the conference.

The following are specific details regarding ACT’s presentation at the
conference:

Stem Cell Meeting on the Mesa’s Second Annual Investor and Partnering Forum

Date:          Monday, Oct. 29
                
Time:           1 p.m. PDT
                
Location:       Sanford Consortium for Regenerative Medicine
                2880 Torrey Pines Scenic Drive, La Jolla, California 92037
                

About the Stem Cell Meeting on the Mesa’s Investor and Partnering Forum

The Investor and Partnering Forum is being organized by the Sanford
Consortium, CIRM and The Alliance for Regenerative Medicine (ARM) to
facilitate translational research, promote engagement between the scientific
and business communities and provide opportunities for business, academic
research and investor participants to connect in one-on-one strategic
partnering meetings. To learn more or to register for the 2011 Stem Cell
Meeting on the Mesa Symposium and Investor & Partnering Forum, please visit
www.stemcellmeetingonthemesa.com.

About Advanced Cell Technology, Inc.

Advanced Cell Technology, Inc., is a biotechnology company applying cellular
technology in the field of regenerative medicine. For more information, visit
www.advancedcell.com.

Forward-Looking Statements

Statements in this news release regarding future financial and operating
results, future growth in research and development programs, potential
applications of our technology, opportunities for the company and any other
statements about the future expectations, beliefs, goals, plans, or prospects
expressed by management constitute forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Any
statements that are not statements of historical fact (including statements
containing the words “will,” “believes,” “plans,” “anticipates,” “expects,”
“estimates,” and similar expressions) should also be considered to be
forward-looking statements. There are a number of important factors that could
cause actual results or events to differ materially from those indicated by
such forward-looking statements, including: limited operating history, need
for future capital, risks inherent in the development and commercialization of
potential products, protection of our intellectual property, and economic
conditions generally. Additional information on potential factors that could
affect our results and other risks and uncertainties are detailed from time to
time in the company’s periodic reports, including the report on Form 10-K for
the year ended December 31, 2011. Forward-looking statements are based on the
beliefs, opinions, and expectations of the company’s management at the time
they are made, and the company does not assume any obligation to update its
forward-looking statements if those beliefs, opinions, expectations, or other
circumstances should change. Forward-looking statements are based on the
beliefs, opinions, and expectations of the company’s management at the time
they are made, and the company does not assume any obligation to update its
forward-looking statements if those beliefs, opinions, expectations, or other
circumstances should change. There can be no assurance that the Company’s
clinical trials will be successful.

Contact:

Investors:
CEOcast, Inc.
James Young, 212-732-4300
or
Press:
ACT Corporate Communications
Bill Douglass, 646-450-3615
or
Russo Partners
Martina Schwarzkopf, Ph.D., 212-845-4292
 
Press spacebar to pause and continue. Press esc to stop.